Back

Pyruvate from bone marrow mesenchymal stem cells supports myeloma redox homeostasis and anabolism

Vera-Siguenza, E.; Escribano-Gonzalez, C.; Serrano-Gonzalo, I.; Eskla, K.-L.; Speakman, C.; Huerta-Uribe, A.; Vettore, L.; Rana, H.; Boufersaoui, A.; Vellama, H.; Nashiebi, R.; Cloete, I.; Roberts, J.; Basu, S.; Drayson, M.; Bunce, C.; Pratt, G.; Spill, F.; Maddocks, O. D. K.; Tennant, D. A.

2024-08-09 cancer biology
10.1101/2024.08.08.607157 bioRxiv
Show abstract

Multiple myeloma is an incurable cancer of plasma cells that depends on the bone marrow for its survival. Despite its prevalence, the molecular mechanisms underlying this malignancy remain poorly understood. In this study, we aim to bridge this knowledge gap by elucidating the metabolic interplay between myeloma cells and bone marrow mesenchymal stem cells (BMMSCs). BMMSCs are crucial in supporting myeloma cell metabolism, contributing to their proliferation, survival, and resistance to chemotherapy. Through a combination of mathematical modelling and experimental co-cultures, we demonstrate that pyruvate - the end product of glycolysis - plays a key role in myeloma cell metabolism. Our findings reveal that myeloma cells predominantly rely on the uptake of pyruvate produced by neighbouring BMM-SCs via the plasma membrane proton-linked monocarboxylate transporters MCT-1 and MCT-2 encoded by the Slc16a1 and a2 genes, respectively. Furthermore, we show that pharmacological inhibition of the MCT-1/2, with AZD3965, triggers a cascade of compensatory metabolic responses, disrupting redox balance and significantly reducing the proliferation capacity of co-cultured myeloma cells.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.